川芎嗪对脓毒症大鼠肝细胞线粒体膜转运功能的保护作用研究
该研究将SD大鼠随机分为假手术组、脓毒症急性肝损伤(SALI)组、川芎嗪治疗组(盲肠结扎穿孔CLP后经尾静脉注射川芎嗪60 mg/kg)和川芎嗪预防组(CLP前7天每日经尾静脉注射川芎嗪60 mg/kg),每组12只。术后10小时取材检测。与SALI组相比,川芎嗪治疗组和预防组血清ALT、AST、m-AST均显著降低,ATP含量、线粒体膜ATP酶活性及AQP8、CPT-1A表达均显著升高。预防组血清AST和m-AST显著低于治疗组。结论提示川芎嗪对SALI大鼠线粒体膜转运功能有保护作用,且预防作用优于治疗作用。
要点
- SD大鼠CLP术后10小时,川芎嗪治疗组和预防组血清ALT、AST、m-AST均显著低于SALI组(均P<0.01)。
- 川芎嗪预防组血清AST(303.9±110.3 U/L)和m-AST(168.2±60.0 U/L)显著低于治疗组(427.0±117.9 U/L、239.6±64.9 U/L,均P<0.05)。
- 川芎嗪治疗组和预防组肝细胞线粒体ATP含量、Na+-K+-ATPase、Mg2+-ATPase、Ca2+-ATPase、Ca2+-Mg2+-ATPase活性均显著高于SALI组(均P<0.01)。
- 川芎嗪治疗组和预防组线粒体膜AQP8和CPT-1A表达均显著高于SALI组(均P<0.01),而CPT-2表达四组间无显著差异。
- 作者认为川芎嗪对SALI大鼠线粒体膜转运水、离子和脂肪的功能有保护作用,且预防作用优于治疗作用。
适用人群与场景
- SD大鼠脓毒症急性肝损伤模型(CLP法建立),每组12只。
处置流程与药物剂量
- 川芎嗪治疗组:CLP后经尾静脉注射川芎嗪60 mg/kg。
- 川芎嗪预防组:CLP前7天每日经尾静脉注射川芎嗪60 mg/kg。
- 术后10小时取腹主动脉血和肝组织检测。
研究设计与关键结果
- 研究类型:动物实验;样本量:每组12只SD大鼠。
- 与SALI组相比,川芎嗪治疗组和预防组血清ALT、AST、m-AST显著降低:ALT(U/L)123.8±32.8、105.0±44.5 vs. 233.0±110.1;AST(U/L)427.0±117.9、303.9±110.3 vs. 742.6±441.4;m-AST(U/L)239.6±64.9、168.2±60.0 vs. 412.8±252.6,均P<0.01。
- 与SALI组相比,川芎嗪治疗组和预防组ATP含量显著升高(nmol/mg):29.5±10.3、34.6±11.2 vs. 19.3±8.8,均P<0.01。
- 与SALI组相比,川芎嗪治疗组和预防组线粒体膜ATP酶活性显著升高:Na+-K+-ATPase(U/mg)3.91±0.30、3.97±0.35 vs. 2.87±0.82;Mg2+-ATPase(U/mg)3.75±0.38、3.88±0.35 vs. 2.64±1.06;Ca2+-ATPase(U/mg)3.15±0.58、2.98±0.31 vs. 1.75±1.25;Ca2+-Mg2+-ATPase(U/mg)3.82±0.31、3.91±0.42 vs. 2.57±1.01,均P<0.01。
- 与SALI组相比,川芎嗪治疗组和预防组线粒体膜AQP8和CPT-1A表达显著升高(以假手术组为100%):AQP8/COX-IV(79.12±7.79)%、(88.40±9.22)% vs.(62.08±11.91)%;CPT-1A/COX-IV(87.92±10.06)%、(84.91±17.48)% vs.(72.11±7.82)%,均P<0.01。
- 川芎嗪预防组血清AST和m-AST显著低于治疗组:AST(U/L)303.9±110.3 vs. 427.0±117.9;m-AST(U/L)168.2±60.0 vs. 239.6±64.9,均P<0.05。
- 线粒体膜CPT-2表达四组间无显著差异。
证据类型、等级与局限
- 证据类型:动物实验(大鼠)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为川芎嗪对SALI大鼠线粒体膜转运水、离子和脂肪的功能有保护作用,且预防作用优于治疗作用。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the protective effect of ligustrazine on the transporting function of hepatocellular mitochondria membrane in the rats with sepsis-induced acute liver injury (SALI).
METHODS: The Sprague-Dawley (SD) rats were randomly divided into sham operation group, SALI group [established by cecal ligation and puncture (CLP)], ligustrazine treatment group (injection of ligustrazine 60 mg/kg through tail vein after CLP) and ligustrazine preventive group (7 days before CLP, ligustrazine was injected daily through tail vein for 60 mg/kg), and there were 12 rats in each group. Abdominal aorta blood and liver were harvested at 10 hours after operation. The content of serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) and mitochondrial aspartate aminotransferase (m-AST) were determined by enzyme coupling rate method. The content of ATP was detected by colorimetric and chemical fluorescein method. The activity of mitochondrial ATPase was detected by phosphorus quantification. The expressions of mitochondrial membrane aquaporin 8 (AQP8) and carnitine palmitoyl transferase (CPT) were detected by Western Blot.
RESULTS: Compared with sham operation group, the levels of serum ALT, AST and m-AST were significantly increased in SALI group, ligustrazine treatment group and ligustrazine preventive group, and the content of ATP was reduced, the activity of mitochondrial membrane ATPase, the expressions of AQP8 and CPT-1A were significantly decreased. Compared with SALI group, the levels of serum ALT, AST and m-AST were significantly decreased in ligustrazine treatment and ligustrazine preventive groups [ALT (U/L): 123.8±32.8, 105.0±44.5 vs. 233.0±110.1; AST (U/L): 427.0±117.9, 303.9±110.3 vs. 742.6±441.4; m-AST (U/L): 239.6±64.9, 168.2±60.0 vs. 412.8±252.6; all P < 0.01], the content of ATP were significantly increased (nmol/mg: 29.5±10.3, 34.6±11.2 vs. 19.3±8.8, both P < 0.01), the activity of ATPase in hepatocellular mitochondrial membrane were significantly increased [Na+-K+-ATPase (U/mg): 3.91±0.30, 3.97±0.35 vs. 2.87±0.82; Mg2+-ATPase (U/mg): 3.75±0.38, 3.88±0.35 vs. 2.64±1.06; Ca2+-ATPase (U/mg): 3.15±0.58, 2.98±0.31 vs. 1.75±1.25; Ca2+-Mg2+-ATPase (U/mg): 3.82±0.31, 3.91±0.42 vs. 2.57±1.01, all P < 0.01], the expressions of AQP8 and CPT-1A were significantly increased [percentage increase from sham operation group (100%), AQP8/COX-IV: (79.12±7.79)%, (88.40±9.22)% vs. (62.08±11.91)%; CPT-1A/COX-IV: (87.92±10.06)%, (84.91±17.48)% vs. (72.11±7.82)%, all P < 0.01]. The levels of serum AST and m-AST in ligustrazine preventive group were significant lower than those in ligustrazine treatment group [AST (U/L): 303.9±110.3 vs. 427.0±117.9; m-AST (U/L): 168.2±60.0 vs. 239.6±64.9, both P < 0.05]. There was no significant difference in the expression of CPT-2 in mitochondrial membrane between the four groups.
CONCLUSIONS: Ligustrazine could play a protective role on the mitochondrial membrane function of transporting water, ion and fat in the rats with SALI. The preventive function of ligustrazine is better than the treatment effect of the rats with sepsis.
参考来源
- Sheng Y, Wang J, Tao X, et al. [Study on the protective effect of ligustrazine on the transporting function of hepatocellular mitochondria membrane in the septic rats]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2018. PMID: 30439325. doi:10.3760/cma.j.issn.2095-4352.2018.010.019
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。